BIOPHARMA-SERVICES-INC.
With their state-of-the-art Phase 1 clinical infrastructure and expert team of scientific and medical personnel, BioPharma has today decided to donate its World Health Organization (WHO) approved facility for coronavirus COVID-19 vaccine research and treatments.
The global community continues to evolve and develop its response to large-scale health issues with organizations such as the Gates Foundation contributing to the development of infectious disease treatments. In the same way, the leaders at BioPharma wish to do their part for vaccine research to help control the growing epidemic of viruses and disease.
We invite all biotech companies working to create a vaccine for the developing global crisis of this novel coronavirus to contact us to discuss how BioPharma’s capabilities and resources can be mobilized to accelerate the development of therapeutic treatments and vaccines.
The BioPharma team has a strong history of philanthropy and has rallied in the past to respond to global medical needs. Dr. Fathi Abuzgaya MD, Chairman of the Board at BioPharma Services, has volunteered his time for medical missions to Libya and performed pro bono work in Canada as part of the University Health Network (UHN). In 2003, as Chief of Staff of Rouge Valley Health System in Toronto, Dr. Abuzgaya was instrumental in the response to the Severe Acute Respiratory (SARS) outbreak and later developing hospital policy for pandemic planning.
Dr. Abuzgaya, who is also a Principal Investigator remarked, “The race is on to shorten the development time of a COVID-19 vaccine. This coronavirus has not yet been categorized as a pandemic but based on what we have learned from SARS, the potential is real. The team here stands ready today to use our early stage medical research capabilities to support the development of a much needed vaccine.“
Renzo DiCarlo, CEO observed, “It truly is our people that differentiate BioPharma Services from other CROs. We are very proud today to offer our Phase I services to assist the global community. We have been an active partner with the USFDA to further drug research and we are well prepared to do the same for this current global need.”
About BioPharma Services Inc.
BioPharma Services Inc. is a full-service Contract Research Organization (CRO) specializing in the conduct of Phase I/IIa and Bioequivalence clinical trials for international pharmaceutical companies worldwide. BioPharma has clinical facilities both in the USA and Canada with a total capacity of 300 beds with access to healthy volunteers and special populations. Headquartered in Toronto, Canada, BioPharma’s comprehensive services also include Bioanalysis at our GLP Certified Laboratory, Scientific and Regulatory Affairs, Biostatistics and Safety Data Analysis (CDISC), Data Management and Medical Writing.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200302005091/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
China’s Top Baijiu Brand Moutai Showcases China's Green Progress in Manufacturing at COP3015.11.2025 17:41:00 CET | Press release
On November 10 local time, the 30th United Nations Climate Change Conference (COP30) opened in Belem, a city in northern Brazil. As one of the activities at the China Pavilion of COP30, the Side Event on Ecological Civilization and Beautiful China Practice was held simultaneously, focusing on ecological civilization, sharing China's experience, and building global consensus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114596036/en/ China Pavilion at COP30 in Belem, Brazil. Addressing the topic of green transformation in traditional industries, You Yalin, Deputy Party Secretary of Kweichow Moutai Co., Ltd., shared the company's green transformation practices and experiences from the perspective of a traditional Chinese liquor producer. “We hope that every bottle of Moutai not only delivers a feast of flavor, but also conveys the idea of harmony between humans and nature. We aim to contribute China's wisdom and Moutai's
Andersen Consulting styrker sine kompetencer inden for digital transformation med Criticalcase14.11.2025 19:44:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer gennem en samarbejdsaftale med Criticalcase, der er et europæisk firma med speciale i cloud-infrastruktur, cybersikkerhed og administrerede it-tjenester. Criticalcase blev grundlagt i 1999 og har hovedsæde i Italien og har markeret sig inden for cloud-sektoren ved at designe og vedligeholde komplekse infrastrukturer for mellemstore og store virksomheder. Gennem skræddersyede løsninger tilbyder virksomheden et omfattende udvalg af tjenester, herunder sikkerhed, overvågning døgnet rundt og systemadministration, hvilket skaber pålidelighed, optimal ydeevne og beskyttelse helt ned til operativsystemniveau. "Vores mission har altid været at guide kunder gennem komplekse teknologiske udfordringer med en strategisk og praktisk tilgang," siger Luca Nunno, der er CEO for Criticalcase. "Samarbejdet med Andersen Consulting giver os mulighed for at få vores ekspertise ud til et bredere globalt publikum og skabe værdi gennem innovation og digital ekspert
Andersen Consulting samarbejder med TruScore14.11.2025 16:15:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med TruScore, som styrker virksomhedens kompetencer inden for humankapital og hjælper kunder med at opbygge stærkere ledelsesteams og organisatoriske kulturer. Truscore, der har hovedsæde i USA, specialiserer sig i at levere fuldt skræddersyede survey-hosting-løsninger, der gør det muligt for organisationer at gennemføre whitelabel-vurderingsordninger, der er skalerbare, sikre og tilpasset deres specifikke behov. TruScore tilbyder avancerede 360-graders feedbackløsninger og samarbejder med Fortune 500-virksomheder, ledelsesudviklingsfirmaer og uafhængige coaches om at designe og administrere deres egne vurderingsplatforme og -oplevelser. "I nutidens dynamiske forretningsmiljø har organisationer brug for mere end blot en strategi – de har brug for stærk og robust ledelse for at kunne omsætte strategien til succes," siger Derek Murphy, CEO for TruScore. "Gennem dette samarbejde med Andersen Consulting kan vi få vores ekspertise inden for
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 13:47:00 CET | Press release
-- Advancing Its Overseas Growth Strategy to Expand Japanese-Quality Aesthetic Medicine Across Asia Following Singapore -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom